News

Harrow states that this transaction will grant US and Canadian commercial rights to six therapeutics, including two non-prescription brands.

The American Society of Retina Specialists (ASRS) Research and Safety in Therapeutics (ReST) Committee has linked Apellis’ pegcetacoplan injection (Syfovre) with a handful of cases of occlusive retinal vasculitis.

According to the ASRS Research and Safety in Therapeutics Committee, ophthalmologists noted instances of intraocular inflammation (IOI) after the initial injection of pegcetacoplan.

Condition is linked to longer resolution times, worse outcomes

SriniVas R. Sadda, MD, discusses being president-elect of ARVO, as well as AI research being conducted at Doheny Eye Institute.

Investigators found that implementing immediately sequential bilateral cataract surgery reduced the number of patient visits by 50%.

According to the company, the transaction includes U.S. and Canadian commercial rights to six therapeutics, including two non-prescription brands.

According to the company, initial interim Phase 2 efficacy data is expected to be presented in H1 2024. It also is expected to provide an update regarding Phase 3 pivotal trial plans in Q1 2024 after discussion with the FDA later this year.

A recent study demonstrates the safety and efficacy of treating eyes with cross-linking after keratoconus relapses following keratoplasty.

Lens is stable in capsular bag, less sensitive to misalignment.

A recent study demonstrates the safety and efficacy of treating eyes with cross-linking after keratoconus relapses following keratoplasty.

Nominations for the 2023 awards will close July 31, 2023.

The oral presentation, entitled “Population Pharmacokinetics and Safety of OPT-302, an anti-VEGF-C/-D ‘trap’ in Patients with Retinal Vascular Diseases” will take place on July 31, 2023 in Seattle, Washington.

The machine learning model analyzes retinal images and associated data and recognizes specific features to identify individuals with mild cognitive impairment.

A trial funded by the National Institutes of Health underscores need for more research to head off high myopia.

The complement system identifies and eliminates pathogens and dying cells, 3 pathways can activate the complement system—classical, lectin, and alternative—and their activation results in similar functions of opsonization, inflammation, and cell lysis.

The authors suggested that future studies of myopia control should test stronger concentrations of atropine.

Nominations for the 2023 awards will close July 31, 2023.

Tenpoint’s aim is to reverse vision loss by generating specialized ocular cell types, both ex vivo and in vivo.

Cognition Therapeutics has dosed the first participant in the phase 2 MAGNIFY study of CT1812. This oral therapy is being studied as a for geographic atrophy (GA) secondary to dry age-related macular edema (AMD).

According to a study, the experimental eye drop treatment was twice as effective as the standard injection therapy at reducing swelling and improving blood flow within the retina of mice with RVO.

While these complications are rare, they require prompt diagnosis and management to prevent serious visual morbidity.

Akari remains on track and plans to submit an IND application to the US FDA in the first half of 2024, and plans on starting clinical trials in the second half of 2024

This certifies that the facility adheres to a comprehensive set of regulatory standards as set by the NABP to ensure safety of drugs and medical devices in the US.

Take a look at a review of the highlights and hottest stories from Ophthalmology Times during the week of July 9, 2023.